A cheaper version of a best-selling rheumatoid arthritis drug will be here in November -- and it's just the start

Wikimedia Commons Pfizer Inc said on Monday it will begin shipping its biosimilar version of Johnson & Johnson's blockbuster rheumatoid arthritis drug Remicade in late November at a 15 percent discount to current wholesale prices. The Pfizer drug, to be sold under the name Inflectra, is already available in Europe and other overseas markets and would be the second biosimilar medicine available in the United States. As it is not possible to produce exact copies of biotech drugs made from living...